Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018
Arecor Ltd, the UK-based leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.
The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today's bioprocessing challenges. Now in its tenth year, the event has grown to include 17 distinct conferences with weeklong programming on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing. Along with the impressive array of conferences, the Summit also includes short courses and training seminars that provide in-depth coverage of critical bioprocess topics. For more information about the summit, please visit http://www.bioprocessingsummit.com/
Arecor’s Chief Scientific Officer, Dr Jan Jezek, will be running one of the Short Courses and will give two presentations with a number of cases studies demonstrating the power of Arecor’s proprietary technology to develop differentiated biopharmaceutical products.
Thursday 16th, 6pm-9pm
Short course: Development of Innovative and Competitive Biologic Formulations in a Complex Patent Landscape
The Biologics market is becoming increasingly competitive due to rapidly expanding pipelines and growing biosimilar competition. Consequently, there are increasing demands for product differentiation. Formulation is one critical part of the drug product development that can deliver such differentiation, for example by achieving improved stability or enabling a desired delivery method. Awareness of patent landscape is a very important aspect of formulation development not only to ensure Freedom-to-Operate but also offering attractive options for patent protection, especially if it enables a product concept that others strive to achieve. This Short Course will demonstrate the importance of intellectual property in formulation design and describe formulation strategies for better products in the complex formulation patent landscape.
Monday 13th, 3:15pm
Formulation Challenges in the Increasingly Complex Patent Landscape
With growing competition in the market and more complex regulatory requirements, the demands for formulation of therapeutic proteins are increasing. In addition, the formulation patent landscape is becoming more complicated which further contributes to the challenge. This talk will describe several examples of successful formulation-related blocking patents as well as strategies for developing successful products in the increasingly complex patent landscape.
Thursday 16th, 9:00am
Successful High-Concentration Products – Creative Formulation and Device Choice
Developing stable, low-viscosity therapeutic protein products is extremely challenging and requires a number of good decisions to be made along the development process with respect to the product concept, formulation, delivery device. The talk will describe innovative formulation approaches enabling differentiated product concepts, as well as examples of intellectual property considerations that have to be taken into account during the development.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: “I am delighted to have the opportunity to present at the Bioprocessing Summit this year. Having attended this conference several times in the past, I know that it is an excellent forum to learn about the latest advances in biopharmaceutical development and have a number of very interesting discussions with a wide range of interesting people. Arecor keeps making great strides in developing highly differentiated biopharmaceutical products through application or our proprietary formulation technology. In order to succeed it is critical for us to keep up-to-date with the latest developments in the industry as well as receiving a constructive feedback on our technology and product strategy. The Bioprocessing Summit is an excellent event to achieve that. ”
About Arecor and its Arestat™technology
Arecor Limited is a technology leader in developing superior liquid formulations of biopharmaceuticals through the application of its proprietary innovative formulation technology platform: Arestat™. Using the platform, Arecor has an excellent track record in delivering highly differentiated formulations of protein- and peptide-based pharmaceuticals as well as many vaccines
Arecor partners with leading pharmaceutical and biotech companies to deliver superior formulations of their exclusive products, across novel products’ pipelines, biosimilars and in lifecycle management. As such, Arecor successfully develops differentiated product profiles, including stable high-concentration biologics with low viscosity and reformulations of lyophilised or freeze-dried products into stable liquids biopharmaceuticals that can be used outside the cold chain.
Furthermore, Arecor is leveraging this platform to develop its own proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Currently such portfolio includes:
- Stable aqueous glucagon for emergency and artificial pancreas use,
- Novel insulin formulations to deliver ultra-rapid acting insulin analogs and,
- Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices and,
- A series of undisclosed pre-clinical programmes.
About Arecor’s Patent Portfolio
Arecor’s technology is protected by 25 patent families, including 26 granted patents.
Please contact us to arrange to meet or speak:
Dr Laura AS Ciccolini, Director of Business Development and Licensing
Tel: +44 (0) 1223 426 060
Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.